Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (261)	1/20/1999 10:40:00 PM
From: Scott H. Davis	Respond to of 626

Market setiment. Development stage biotechs under $100 m are avoided by funds & institutions, plus the large brokeages won't recommend anything under $5.00, and some $10.00. Known promlem that development stage biotechs need more funds to cover costs until they have profitible drug, and demand for capital far exceeds supply for biotechs. Then there's biotech itself. appeals to smaller pool of investors due to DD needed in a field where most folks are otherwise clueless. For example, I remember Perer Lynch stating that he does not buy biotechs since he doesn't understand them. How's that 4 starters. Yet, these are some potential huge winners. I'm quite willing to place my money on the line with the likes of ISIP, VICl, LGND, AGPH, MLNM. They're too far along the development curve, have too much technology validation at this point. IMSCO Scott